These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10854173)

  • 1. Approaches for immunotherapy of lymphomas.
    Kwak LW
    Immunol Invest; 2000 May; 29(2):93-5. PubMed ID: 10854173
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of lymphoid tumors with anti-idiotype antibodies.
    Stevenson GT; Stevenson FK
    Springer Semin Immunopathol; 1983; 6(1):99-115. PubMed ID: 6351310
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigen-induced murine B-cell lymphomas. III. Passive anti-idiotype serum therapy and its combined effect with chemotherapy.
    Lanier LL; Babcock GF; Lynes MA; Haughton G
    J Natl Cancer Inst; 1979 Dec; 63(6):1417-22. PubMed ID: 316036
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer vaccine strategies get bigger and better.
    de Gruijl TD; Curiel DT
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract]   [Full Text] [Related]  

  • 5. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract]   [Full Text] [Related]  

  • 8. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-Hodgkin's lymphoma: identification of the monoclonal B lymphocyte component in the presence of polyclonal immunoglobulin.
    Wood GW; Travers H
    J Histochem Cytochem; 1982 Oct; 30(10):1015-21. PubMed ID: 6813369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes.
    Levy R; Meeker T; Lowder J; Levy S; Thielemans K; Warnke RA; Cleary ML; Sklar J
    Symp Fundam Cancer Res; 1986; 38():261-8. PubMed ID: 3529276
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma.
    Nelson EL; Li X; Hsu FJ; Kwak LW; Levy R; Clayberger C; Krensky AM
    Blood; 1996 Jul; 88(2):580-9. PubMed ID: 8695806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
    Marron TU; Ronner L; Martin PE; Flowers CR; Brody JD
    Immunotherapy; 2016 Nov; 8(11):1335-1346. PubMed ID: 27993085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
    J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy in follicular lymphoma.
    Veelken H
    Semin Cancer Biol; 2003 Jun; 13(3):241-7. PubMed ID: 12959355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of B cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum.
    Lanier LL; Babcock GF; Raybourne RB; Arnold LW; Warner NL; Haughton G
    J Immunol; 1980 Oct; 125(4):1730-6. PubMed ID: 6997386
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
    Tamura GS; McGrath MS; Weissman IL
    J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of innate and induced anti-idiotypic mechanisms in suppression of B cell tumors.
    Stevenson FK; George AJ; Tutt AL; Glennie MJ; Stevenson GT
    Monogr Allergy; 1987; 22():184-93. PubMed ID: 3501833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.